title: A rare bladder cancer--small cell carcinoma: review and update.
abstract: Small cell carcinoma of the bladder (SCCB) is rare, highly aggressive and diagnosed mainly at advanced stages. Hematuria is the main symptom of this malignancy. The origin of the disease is unknown; however the multipotent stem cell theory applies best to this case. Histology and immunohistochemistry shows a tumour which is indistinguishable from small cell lung carcinoma (SCLC). Coexistence of SCCB with other types of carcinoma is common. The staging system used is the TNM-staging of bladder transitional cell carcinoma. The treatment is extrapolated from that of SCLC. However, many patients with SCCB undergo radical resection which is rarely performed in SCLC. Patients with surgically resectable disease (< or = cT1-4aN0M0) should be managed with multimodal therapy associating chemotherapy, surgery and/or radiotherapy. Neoadjuvant chemotherapy using four chemotherapy cycles followed by radical cystectomy is the most effective therapeutic sequence. Patients with unresectable disease (> or = cT4bN+M+) should be managed with palliative chemotherapy based on neuroendocrine type regimens comprising a platinum drug (cisplatin in fit patients). The prognosis of the disease is poor mainly in the case of pure small cell carcinoma. Other research programs are needed to improve the outcome of SCCB.
authors.affiliation: Medical oncology, centre régional d'oncologie, Agadir, Morocco. ismailinabil@yahoo.fr
authors.forename: Nabil
authors.initials: N
authors.lastname: Ismaili
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols; D018288:Carcinoma, Small Cell / Q000453:epidemiology / Q000473:pathology / Q000601:surgery / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011379:Prognosis; D011878:Radiotherapy; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000601:surgery / Q000628:therapy
references.citation: J Urol. 1995 Jun;153(6):1820-2
references.pmid: 7752326
references.citation: Cancer. 1999 Dec 1;86(11):2346-52
references.pmid: 10590377
references.citation: Br J Cancer. 2010 Feb 16;102(4):629-38
references.pmid: 20104223
references.citation: Cancer. 1985 Nov 15;56(10):2530-3
references.pmid: 2994881
references.citation: Cancer Treat Rev. 2006 Dec;32(8):588-93
references.pmid: 17008012
references.citation: Cancer. 1981 Feb 15;47(4):724-30
references.pmid: 6261916
references.citation: Bull Cancer. 2009 Jun;96(6):E30-44
references.pmid: 19457759
references.citation: Prog Urol. 2011 Jun;21(6):369-82
references.pmid: 21620296
references.citation: BJU Int. 2004 Jul;94(1):12-7
references.pmid: 15217423
references.citation: Bull Cancer. 2002 Feb;89(2):166-73
references.pmid: 11888856
references.citation: Cancer. 1992 Jan 15;69(2):527-36
references.pmid: 1309435
references.citation: J Cancer Res Ther. 2009 Apr-Jun;5(2):133-6
references.pmid: 19542673
references.citation: BJU Int. 2009 Mar;103(6):747-52
references.pmid: 19076139
references.citation: Mod Pathol. 2005 Mar;18(3):320-3
references.pmid: 15502806
references.citation: Hum Pathol. 2005 Jul;36(7):718-23
references.pmid: 16084939
references.citation: Indian J Urol. 2008 Oct;24(4):494-7
references.pmid: 19468504
references.citation: Clin Cancer Res. 2007 Feb 1;13(3):953-7
references.pmid: 17289890
references.citation: Ann Oncol. 2010 Nov;21(11):2240-2245
references.pmid: 20427346
references.citation: J Urol. 2004 Aug;172(2):481-4
references.pmid: 15247709
references.citation: Clin Oncol (R Coll Radiol). 2004 Dec;16(8):523-7
references.pmid: 15630844
references.citation: Mod Pathol. 2000 Mar;13(3):238-42
references.pmid: 10757334
references.citation: Pathol Int. 2009 Apr;59(4):247-50
references.pmid: 19351368
references.citation: Histopathology. 1999 Aug;35(2):150-6
references.pmid: 10460660
references.citation: Urology. 2005 Feb;65(2):295-9
references.pmid: 15708041
references.citation: Histopathology. 2005 Jan;46(1):57-63
references.pmid: 15656887
references.citation: Urol Oncol. 2012 Mar-Apr;30(2):192-5
references.pmid: 20363163
references.citation: Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):8-18
references.pmid: 17536302
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2592-7
references.pmid: 19414678
references.citation: Histol Histopathol. 2010 Feb;25(2):217-21
references.pmid: 20017108
references.citation: Cancer. 2005 Mar 15;103(6):1172-8
references.pmid: 15700264
references.citation: Cancer. 1989 Sep 15;64(6):1347-57
references.pmid: 2548704
references.citation: World J Urol. 2009 Feb;27(1):101-6
references.pmid: 18607595
references.citation: J Pathol. 1999 Oct;189(2):230-5
references.pmid: 10547580
references.citation: J Urol. 2005 Jul;174(1):93-6
references.pmid: 15947585
references.citation: J Urol. 1998 May;159(5):1624-9
references.pmid: 9554367
references.citation: Expert Rev Anticancer Ther. 2006 Dec;6(12):1707-13
references.pmid: 17181484
references.citation: BMC Urol. 2009 Jun 06;9:4
references.pmid: 19500382
references.citation: Diagn Cytopathol. 1996 Jun;14(4):292-7
references.pmid: 8725127
references.citation: Urol Oncol. 2009 Jan-Feb;27(1):3-7
references.pmid: 18367107
references.citation: Eur Urol. 1999 Apr;35(4):323-6
references.pmid: 10087396
references.citation: Cancer. 2004 Sep 1;101(5):957-62
references.pmid: 15329903
references.citation: Cancer. 1997 Jan 15;79(2):356-61
references.pmid: 9010109
references.citation: J Urol. 1991 Aug;146(2):382-8
references.pmid: 1713277
references.citation: Cancer. 1990 May 1;65(9):1928-36
references.pmid: 2164873